SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending amidst escalating geopolitical tensions, primarily driven by fresh tariff threats from the US administration against European allies, particularly in light of controversial rhetoric regarding Greenland. This has ignited a sharp division among investors, with many anticipating a significant market pullback, while others strongly believe in a swift "buy the dip" recovery, further complicated by discussions around the Japan bond market's stability.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as escalating geopolitical tensions, fueled by threats of tariffs and a looming Supreme Court decision on trade policy, generate significant market uncertainty. Community sentiment is sharply divided between those predicting a substantial market downturn due to political instability and those advocating to "buy the dip," expecting resilience from tech and growth stocks.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following Saudi Arabia's approval of its Anktiva-based Bioshield protocol for non-small cell lung cancer and broader cancer treatment, alongside ongoing discussions with the FDA for papillary bladder cancer. The community is passionately discussing the potential for a significant short squeeze, viewing the company as a disruptive force in oncology while expressing strong frustration with perceived FDA delays.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. (DJT) is trending amidst intense debate spurred by former President Trump's controversial push for tariffs against European nations, reportedly tied to his interest in Greenland and past grievances. This situation has ignited polarized community discussions concerning potential trade wars and geopolitical repercussions, with many weighing economic stability against his "America First" agenda.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is a prominent trending topic, experiencing pre-market declines amid broader market volatility and geopolitical trade tensions. The community is actively debating a potential "red to green" recovery, with bulls "buying the dip" while bears highlight growing competition from international EV brands and express skepticism about the company's ambitious AI and robotics initiatives. This discussion occurs as the market anticipates upcoming earnings and recent news regarding the company's accelerated AI chip development.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as investors react to confirmed ongoing collaboration with Celestial AI, now acquired by Marvell, validating POET's pivotal role in next-gen AI optical interconnects. The community is buzzing about the company's patented Optical Interposer and its passive alignment technology, which enables highly efficient wafer-scale optical transceiver assembly for AI data centers. Anticipation is high for upcoming customer announcements and the imminent disclosure of fundamental investors, despite ongoing market manipulation concerns.

BlackRock Institutional Trust Company N.A. - iShares Russell 2000 ETF

iShares Russell 2000 ETF

The iShares Russell 2000 ETF (IWM) is a central topic amidst escalating trade tensions regarding potential US tariffs on EU goods, stemming from geopolitical demands, and an awaited Supreme Court ruling on existing tariffs. Despite this policy uncertainty, IWM is displaying remarkable relative strength, consistently reaching new highs and outperforming large-cap indices. This robust small-cap performance is prompting community debate, with some viewing it as a healthy market rotation and broadening of growth, while others express caution regarding the profitability of some underlying companies.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin (APP) is trending following an investigative report alleging the company's involvement in money laundering for a Southeast Asian gambling group, which has sparked a sharp market sell-off. While some in the community are expressing serious concerns and anticipating further declines, many long-term investors are dismissing the report as a rehashed short attack and are actively buying the dip, expecting a strong rebound following upcoming earnings and management's anticipated defense of the allegations.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. (CRML) is drawing significant market attention amidst escalating geopolitical discussions surrounding Greenland's vast critical mineral resources and the strategic imperative to secure rare earth supply chains. Community discussion is buzzing around the company's established partnerships for rare earth processing and expectations for updates from a highly anticipated business call, all set against a backdrop of increasing global demand for strategic metals.

Venture Global, Inc. engages in the development and construction of liquefied natural gas production, establishing us as a rapidly growing company delivering critical LNG to the world. It projects include Calcasieu, Plaquemines, CP2, CP3 and Delta projects. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is actively trending as investors monitor escalating European natural gas demand driven by colder weather and low storage levels, coupled with the rapid production ramp-up at its Plaquemines facility. The community is highly focused on favorable natural gas price spreads and substantial short interest, anticipating that the stock is significantly undervalued given its accelerating output and growth trajectory. Many believe that ongoing arbitration concerns are overblown, positioning Venture Global to become a dominant global LNG exporter amid robust market demand.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The firm is scheduled to report its financial performance for Q4 and fiscal 2025 ahead of the market open on Tuesday, Feb. 10, 2026.</li><li>The company’s total revenue for fiscal 2025 is projected around $370.2 million to $370.4 million.</li><li>Looking ahead, the company has set a revenue forecast for fiscal 2026 between $365 million and $375 million.</li></ul>InMode (INMD) stock is gaining investor attention in Friday’s premarket after the medical technology provider announced its fourth quarter (Q4) sales outlook.The company said it anticipated its fourth-quarter (Q4) sales to fall within a tight range of $103.6 million to $103.8 million, compared with the analyst consensus estimate of $104.64 million, according to FiscalAI data.&nbsp;<h2 class="st-heading-2">2025 And 2026 Outlook&nbsp;</h2>The firm is scheduled to report its financial performance for Q4 and fiscal 2025 ahead of the market open on Tuesday, Feb. 10, 2026. The company’s total revenue for fiscal 2025 is projected to be around $370.2 million to $370.4 million, below the analysts' consensus estimate of $371 million, as per FiscalAI data.InMode expects a non-GAAP gross margin near the high end of the 70% range for the full 2025 fiscal year.&nbsp;Looking ahead, the company has set a revenue forecast for fiscal 2026 between approximately $365 million and $375 million.&nbsp;<a href="https://stocktwits.com/symbol/INMD">InMode stock</a> inched 0.8% higher in Friday’s premarket.&nbsp;<h2 class="st-heading-2">What Are Stocktwits Users Saying?&nbsp;</h2>On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory while message volume shifted to ‘high’ from ‘normal’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_09_055125_png_79a97af5f3.webp" alt="INMD’s Sentiment Meter and Message Volume as of 05:45 a.m. ET on Jan. 9, 2026 | Source: Stocktwits" width="926" height="105"></figure>A bullish Stocktwits user highlighted sequential growth and high margins.&nbsp;<stembedurl>https://stocktwits.com/thinkandpick/message/641307067</stembedurl>Another user pointed to ongoing pressure in the aesthetic device sector, noting that demand remains subdued, but added that the latest outlook broadly aligns with the company’s earlier outlook for 2025, suggesting performance is tracking as expected.<stembedurl>https://stocktwits.com/findingthestock/message/641285697</stembedurl><h2 class="st-heading-2">Brokerage Radar&nbsp;</h2>In December, Canaccord cut its price target on InMode to $15 from $16 and kept a ‘Hold’ rating on the stock, according to TheFly. The firm said it still has a positive long-term view on the medical technology industry going into 2026, noting that mid-sized company valuations remain low, and deal activity is increasing.INMD stock has declined by over 10% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-big-oil-invest-at-least-100-billion-venezuela/cmU29w3R4d2">Trump Says Big Oil Will Invest At Least $100 Billion To Rebuild Venezuela's Oil Infrastructure</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 A worker produces medical instrument at Shandong Yixing Medical Instrument Co., Ltd.

INMD Stock Draws Investor Attention On Q4 Financial Update

The company said it anticipated its fourth-quarter (Q4) sales to fall within a tight range of $103.6 million to $103.8 million, compared with the analyst consensus estimate of $104.64 million, according to FiscalAI data. 

Equity

The company said it anticipated its fourth-quarter (Q4) sales to fall within a tight range of $103.6 million to $103.8 million, compared with the analyst consensus estimate of $104.64 million, according to FiscalAI data. 


UBS says this sector remains a high-quality, defensive investment theme

Investing.com -- UBS continues to view the medical devices sector as a high-quality, defensive investment theme, supported by long-term demographic shifts and rising global demand.

Citi shuffles MedTech stocks: BDX downgraded, ITGR raised; reiterates top pick

Investing.com -- Citi analysts revised their MedTech coverage following a volatile first quarter, with several rating changes and adjustments to target prices.

HSBC shuffles MedTech stocks, cutting 4, upgrading 2

Investing.com -- HSBC has reshuffled its ratings across the MedTech and Life Sciences sector, upgrading   Siemens  Healthineers AG  (ETR:SHLG) and Sonova (SIX:SOON) to Buy while cutting  Align Technology  (NASDAQ:ALGN), Eurofins Scientific SE (EPA:EUFI), IQVIA, and Smith&Nephew (LON:SN) to Hold.

Are Wall Street Analysts Predicting Cooper Companies Stock Will Climb or Sink?

Cooper Companies has underperformed the broader market over the past year, but analysts are highly optimistic about the stock’s prospects.

DexCom, a manufacturer of glucose monitoring systems for diabetes management, witnessed a 19% rise in the number of watchers on Stocktwits over the last week. The renewed interest in the stock came after the firm surprisingly trimmed its full-year sales forecast, a move that immediately pushed its shares down by 40%.The firm now anticipates full-year revenue of $4.00-$4.05 billion versus an earlier guidance of $4.20-$4.35 billion. Analysts did not take the significant revision lightly and raised concerns during the earnings call. DexCom management cited factors like sales force disruption and a decline in market share as some of the primary reasons that led to the guidance trim.Meanwhile, the company reported a 15% rise in its second quarter revenue at $1 billion while net income rose 24%YoY to $143.50 million. Volume growth in conjunction with strong new customer additions continued to be the primary driver of revenue growth.The firm’s sensor segment witnessed a 22% YoY rise in revenue at $947 million while hardware revenue declined 39% to $57.30 million.Kevin Sayer, Dexcom’s chairman, president and CEO stated that the firm’s execution did not meet its high standards. The firm cited a decline in new customers, lower revenue per patient and higher-than-expected rebates as reasons for its sales guidance cut.Meanwhile, JPMorgan downgraded the stock to ‘Neutral’ from ‘Overweight’ while reducing the price target to $75 from $145. The firm’s analyst said the second-quarter update was a sharp turn in the wrong direction for the firm.However, retail sentiment is currently trending in the bullish territory (56/100) as investors’ confidence was buoyed by the firm’s $750 million share repurchase program.<figure class="image"><a href="https://stocktwits.com/symbol/DXCM"><img style="aspect-ratio:790/219;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_07_31_at_12_31_30_PM_317bed394d.png" alt="Stocktwits sentiment trends in bullish zone for DexCom" width="790" height="219"></a><figcaption>Stocktwits sentiment trends in bullish zone for DexCom</figcaption></figure>DexCom hasn’t recovered from the 40% decline but retail investors anticipate the share repurchase may help in recouping some of the losses. One Stocktwits user named ‘MoonWalk3000’ expressed optimism about the company’s buyback decision and said this is a good way to improve the book value of the stock.<figure class="image"><a href="https://stocktwits.com/MoonWalk3000/message/580825054"><img style="aspect-ratio:788/695;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_07_31_at_12_32_42_PM_927efc54e2.png" alt="Stocktwits user MoonWalk3000's post on DexCom" width="788" height="695"></a><figcaption>Stocktwits user MoonWalk3000's post on DexCom</figcaption></figure>

DexCom Crashed 40% In A Single Day Last Week; Gains 19% More Stocktwits Watchers

The firm revised down its full-year sales guidance which led to a slew of analyst downgrades. Retail investors are betting on the $750 million share repurchase program announced by the firm to buoy shares.

Current Price	$89.57
Prev Close	$89.66
Open	$90.06
Dividend Yield	N/A
50-Day Moving Average	$87.45
Beta	N/A
Avg. Volume	11,131.68
PE Ratio	N/A

52-Week High	$97.10
52-Week Low	$71.25
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

XHE
SPDR S&P Health Care Equipment ETF

Feed

News

Sentiment

Fundamentals

Info

Latest XHE News

XHESPDR S&P Health Care Equipment ETF